S&P 500 7,679.03 +1.45%
Nasdaq 25,758.42 +1.52%
S&P/TSX 36,105.47 +1.61%
Apple 352.66 +6.25%
Nvidia 202.64 −1.96%
Microsoft 552.57 +6.06%
Shopify 211.61 +5.70%
Royal Bank 290.50 +1.78%
CAD/USD 0.7165 +0.19%
LIVE · 11:10 ET
Market ClerkRecap
Wed Nov 4 · markets open3 signals today175 insider buys this week · $365.2MCIRO short report next: Nov 15The week ahead

KYNB

KYNTRA BIO, INC.
NASDAQ · HEALTH CARE · PHARMACEUTICAL PREPARATIONS
4.31
−0.15 −3.36%
USD · close Nov 3

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $17.5MP/E 0.1DIV YIELD —FCF YIELD -218.10%REV TTM $4.6M −37.1%NET INCOME $183.2MNET DEBT $24.4M52W 4.31 – 11.03SEC XBRL · TTM TO Invalid Date

Who holds it

SEC 13F · LATEST QUARTER PER FUND
None of the 15 tracked funds disclose KYNB in their latest 13F. The funds we follow.

13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.

Stakes of 5% or more

SCHEDULE 13D / 13G · LATEST PER HOLDER · TWO YEARS
No 13D or 13G filing on KYNB in the last two years from the filings we read (13G only for companies we track; the sweep began Sep 2026).

A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.

Watch KYNB. Know when insiders buy.
One email the day a filing lands. Free.